BLOCK LISTING SIX MONTHLY RETURN
(Note: Italicised terms have the same meaning as given in the Listing Rules.)
Date: 29 April 2019
| Name of applicant: | Summit Therapeutics plc | |||
| Name of scheme: | 2005 EMI Scheme | |||
| Period of return: | From: | 30 Sep 2018 | To: | 31 Mar 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 4,402,293 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Zero | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Zero | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 776,756 † | |||
| Name of applicant: | Summit Therapeutics plc | |||
| Name of scheme: | 2016 Long Term Incentive Plan | |||
| Period of return: | From: | 30 Sep 2018 | To: | 31 Mar 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 4,196,863 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Zero | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Zero | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 4,196,863 | |||
| Name of contact: | Richard Pye |
| Telephone number of contact: | +44 (0)1235 443951 |
† This figure has been reduced since the last block list review to reflect the number of share options that remain in existence under the 2005 EMI Scheme. This change is due to the voluntary surrender of share options, as announced by regulatory information service on 8 October 2018, that included options awarded under the 2005 EMI Scheme. Other share options issued under the 2005 EMI Scheme lapsed due to employees leaving the Company and these changes are also reflected in the reduced figure. No new share options will be issued under the 2005 EMI Scheme.